Prosthesis Mismatch in TAVR: It’s Real Impact

Prosthesis-patient mismatch (PPM) was initially proposed by Rahimtoola and reintroduced by Pirabot.

La prudencia es buena consejera para decidir una transfusión en el TAVI

PPM is the indexed effective orifice area in relation to body surface area, cutoff value being 0.85 cm2/m2, and <0.70 cm2/m2for obese patients. PPM is considered moderate if indexed effective orifice area is 0.65-0.85 cm2/m2 and severe when <0.65 cm2/m2 

Research studies on surgical prosthesis have associated PPM with higher mortality at short, mid and long term. 

There are few studies on post TAVR PPM. Unlike surgical prosthesis, its impact remains to be shown. 

The current study is a meta-analysis of 23 studies with a total 81969 patients. 19612 presented some degree of PPM (23.9%).

Mortality was higher in patients presenting moderate/severe PPM (HR: 1.09 [95% CI: 1.04-1.14]; P < 0.001).

Within the first 30 months, mortality was higher in patients with moderate to severe PPM (HR: 1.1 [95% CI: 1.05-1.16]; P < 0.001). After 30 days, even though mortality was slightly higher, it did not reach statistical significance (HR 0.83 [95% CI: 0.68-1.01]; P = 0.064).

Read also: AQCA Study: Pre-PCI Virtual QFR for Planning PCI vs. Conventional Angiography.

Additionally, PPM moderate and severe were looked at separately, resulting in higher mortality the with more severe PPM, vs. patients with no PPM (HR: 1.25 [95% CI: 1.16-1.36]; P < 0.001). However, this was not the case when looking at moderate PPM (HR: 1.03 [95% CI: 0.96-1.10]; P = 0.398). 

Conclusion

Severe PPM was associated to higher mortality at TAVR followup (unlike moderate PPM). These outcomes call for strategies to prevent severe PPM. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement Meta-Analysis of Kaplan-Meier–Derived Individual Patient Data.

Reference: Michel Pompeu Sá, et al. J Am Coll Cardiol Img 2023;16:298–310.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...

Can Coronary CT Angiography Replace Invasive Coronary Angiography in Pre-TAVI Coronary Assessment?

Coronary artery disease coexists in approximately half of patients undergoing transcatheter aortic valve implantation, making coronary assessment prior to the procedure essential. Invasive coronary...

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...